Biotech Values

[semi_infinite]

MYOK - You are aware of my past skepticism and my thoughts wrt to myk461 are as summarized below.

1. The proposed mechanism for relieving oHCM pressure gradient is to address hypercontractility in patients with high LVEF. It appears to be working in small P1 study. The conventional view of oHCM is that it is a structural disease. ie septum obstruction and in limited cases valve leaflet obstruction. That is why surgery works and also why alcohol ablation works, works in this case means long term cures. MYK461 does not do anything for heart anatomy problems in oHCM. I remained to be convinced that addressing hypercontractility in HCM would do anything for those patients as well.

2. Even if data is encouraging, the proposed enrollment of 200-259 will be way too small to access potential safety, the need for long term use and safety for long term use. As reference, Entresto trial enrolled >8000 and took years (Paradigm-HF).

I am thinking of shorting via options.